Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (September 2018)
27 slides from Inspiremd's investor presentation, Sep 6, 2018
Slide 1: Investor Presentation
inspireMD Investor Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements inspireMD This presentation contains "forward-looking statements." Such statements may be preceded by the words “intends,""may," "will," "plans,""expects," "anticipates, "projects," "predicts,""estimates,""aims," "believes," "hopes," "potential" or similar words. Forward-l
Slide 3: About InspireMD
About InspireMD inspire InspireMD is a commercial-stage medical device company developing and marketing innovative embolic prevention systems (EPS), with a primary focus on preventing stroke in patients with carotid artery disease (CAD) PRODUCTS Commercial: E ee ~ technol CGuard™ EPS (Carotid) <3 MG
Slide 4: Company Highlights
Company Highlights inspireMD + Fourconsecutive quarters of year over year growth in excess of 50% + Firsthalf2018 vs. first half of 2017 growth of greater than 65% + Fourconsecutive quarters of year over year growth for CGuard in excess of 90% + Growth of CGuardin excess of 110% first half 2018 vs.
Slide 5: Stroke: the second biggest cause of death globally
a Stroke: the second biggest cause of death globally inspireliD + Thereare 15 million new strokesa year * * $34BBin healthcare costsin the U.S. is associated with 3 + [n2016, 5.7 million deaths, were caused by stroke’ stroke management . ill 2 + 5 million people/year are left permanently disabled* 2
Slide 6: Stroke prevention in carotid artery disease: Surgery vs. Stenting
Stroke prevention in carotid artery disease: a Surgery vs. Stenting inspireliD Based on the CREST clinical trial data, in which only conventional carotid stents were used Carotid Endarterectomy Filter Protected Stenting (CEA) (CAS) + Low stroke risk’, but... + Patient friendly, long-term + Invasive;
Slide 7: The potential paradigm shift with CGuard
The potential paradigm shift with CGuard™ inspireMD Carotid procedures tomorrow Carotid procedures today are could be mostly minimally invasive with CGuard™ primarily surgical =CEA @CAS @CcAS 80% of Market MicroNet™ coveredstents could becomethe Gold Standard = 20% of Market 100% of addressable mark
Slide 8: Embolization Following Carotid Artery Stenting
Embolization Following Carotid Artery Stenting inspireMD Plaque protrusion through stent struts occurs in up to 65% of conventional carotid stents in relation to plaque morphology/symptomatic status and stent type, providing a mechanism for post carotid artery stenting (CAS) cerebral embolization, e
Slide 9: Consequences Range from Neurological
Consequences Range from N eurological Pre-Procedure Pre-intervention showing 90% occlusion of the carotid artery and an MRI showing an old white matter infarction (obstruction) Post-Procedure Post.intervention showing successful opening of the occluded carotid artery with conventional stenting and a
Slide 10: CGuard EPS has been shown to prevent embolic debris
CGuard™ EPS has been shown to prevent embolic debris passing into the carotid artery inspirelD Conventional Carotid Stent Carotid plaque can protrude through the mesh Plaque protrusion may lead to early and late distal embolization Denis ~y Arterial if Wall & Image presented at TCT 2014 https:/www.t
Slide 11: Conventional Carotid Stents vs CGuard EPS
. . ™ 2 Conventional Carotid Stents ' CGuard™ EPS No plaque coverage - leading to plaque protrusions The MicroNet™ permanently covers plaque and or prolapse passing into the vessel lumen prevents “debris” from passing through the mesh. Conventional Stent f 4 MicroNet mesh preventing prolapse *Yoshim
Slide 12: Positive CGuard Clinical Experience
Positive CGuard™ Clinical Experience inspireMD CARENET Clinical Trial (2014) 30 Patient Safety and Efficacy clinical trial Zero major adverse cardiac or cerebral events (MACCE) at 30 days (Comparative data 5.72%*) 50% fewer new ischemiclesions with lesion volume being 10x times smaller comparedto hi
Slide 13: Additional Independent Clinical Data
Additional Independent Clinical Data inspireMD "SPECIAL ARTICLES The Iron-Guard Registry Jowoouscsaa ssn + Physician initiated Physician-initiated prospective Italian Registry + 12 large Italian medical centers of carotid stenting with the C-Guard mesh-stent: + 200 patients the IRON-Guard registry.
Slide 14: CGuard EPS vs conventional stents and surgery
CGuard™ EPS vs conventional stents and surgery inspireMD + CGuard™ is a widely researched next generation carotid device stent (7 completed clinical trials and 4 ongoing trials) * CGuard™ shows strong benefits compared to both conventional carotid stents and surgery + Long term sustained and consist
Slide 15: A leading vascular surgeon's view
Aleading vascular surgeon’s view inspireMD GAs a vascularsurgeon! am very experienced with CEA. From my perspective the near future will show a shift towards carotid stenting because of mesh covered stents. The CGuard™, in comparison to other [carotid] stents, even in comparison to other mesh covere
Slide 16: CGuard EPS - accelerating sales growth
CGuard™ EPS - accelerating sales growth inspireMD + Growth continues to accelerate for 2018/2017 Year End Sales in USD Half Year Sales in USD 2,500,000 1,400,000 4,200,000 4,164,000 4,922,000 2,000,000 111% Growth |. 1,000,000 a 68% Growth E 1,500,000 . = 800,000 789,008 1,147,000 4,000,000 Son.o0d
Slide 17: Accelerating CGuard EPS sales growth: Italy
: aN. Accelerating CGuard™ EPS sales growth: Italy inspireliD + CGuard™ sales in Italy have been strong over the last three years with continuing momentum * Q2 comparisons between 2017 and 2018 show a 69% increase Italy CGuard sales in USD Italy First Half 2017 and 2018 600,000 556,000 CGuard sales
Slide 18: CGuard EPS - Germany
CGuard™ EPS - Germany inspireMD + New Distributor in Q2 2017 + Growth Trendis accelerating Half Year Sales in USD 500,000 450,000 435,000 400,000 64% Growth 350,000 300,000 250,000 200,000 150,000 100,000 50,000 0 J a Second Half 2017 First Half 2018 18
Slide 19: CGuard: market potential in stroke prevention
CGuard™ : market potential in stroke prevention inspireMD Proportion of diagnosed HGCS patients who received treatment in 2016 600,000 1,600,000 uNottreated = Treated 2017 Health Research international Market Report 19
Slide 20: Implementing our commercial strategy: Overview
Implementing our commercial strategy: Overview inspireMD InspireMD is seeking to become the leading stroke prevention company, focused on reducing the global burden of stroke -Transition current users of conventional carotid stents to CGuard™ * Persuade current users of conventional carotid stents t
Slide 21: CGuard Product Development
CGuard™ Product Development inspireMD * USFDA + Pre-IDE FDA submission for CGuard™ February 2017 =) IN + Formal FDA meeting held April 2017 * 9 months of pre-clinical work required to file IDE application to begin a US clinical trial « Next generation CGuard™ - 5 French CGuard™ + Minimally invasive
Slide 22: Recent/Upcoming Anticipated Milestones
Recent/Upcoming Anticipated Milestones inspireMD Continued clinical trial/registry results CGuard Partnership in approval and Major Asia launch in Pacific Market Mexico: 2019 H2 2018 ard submission H2 2019 Establish CGuard . Centers of approval in CGuard U.S. Excellence Brazil and IDE submission H1:
Slide 23: Intellectual Property Portfolio
Intellectual Property Portfolio inspireMD + Proprietary platform technology supported by a robustintellectual property portfolio * Continue to strengthen and broaden patent protection globally to enable future pipeline products PATENTRIGHTS ISSUED ALLOWED PENDING Rest of World 35 2 19 23
Slide 24: Leadership
. Ne Leadership inspirelViD Significant track records of success Presidentand CEO gBostong (Pfizer) oe @ ¢ Director SBR ie Gm Lu Director Oteantow ,. Cordis. Bssyasn Director aa raya Special Advisor to the Board Gow ra7i 24
Slide 25: Summary
Summary inspireMD + Focused on preventing stroke that is estimated to cost the US healthcare system more than $34BB annually + The current addressable market for CGuard ™ EPS is estimated to be $1BB with the potential to further expand into the 1.6MM patient population which is diagnosed but not tre
Slide 26: Financial Snapshot
Financial Snapshot inspireMD NYSE AMER: NSPR Stock Price (8/31/2018): $0.19 Average 3 Month Volume (8/31/2018): 770K Shares Outstanding (8/31/2018): 23.8M Shares Outstanding Including full conversion of 44.7M preferredshares and prefunded warrants (8/31/2018): ° Market Capitalization including full
Slide 27: InspireMD contact
inspireMD James Barry, Ph.D., Presidentand CEO Craig Shore, CFO 888.776.6804 888.776.6804 jimb@inspiremd.com craigs@inspiremd.com